MEDANTA

– On the Surgical Edge of Growth

Medanta (Global Health Ltd.), founded in 2009 by Dr. Naresh Trehan, is among India’s top hospital chains with presence in Gurugram, Lucknow, Indore, Patna, Ranchi & more. Known for super-specialty care in cardiac, neuro, oncology, orthopaedics & transplants, it blends clinical excellence with research, building strong investor trust. Fundamentals: Q1 FY26 net profit +17% YoY with margin gains. TTM revenue ~₹3,861 cr, net income ~₹534 cr, EPS ~₹19.9. ROE ~15%, debt-light, forward P/E ~58. New capacity (Ranchi operational, Assam in pipeline) supports medium-term growth. Technicals: CMP ₹1,423, near 52W high ₹1,456, above 100-DMA ₹1,234 & 200-DMA ₹1,195 — bulls in control. RSI ~72 signals strong momentum. Breakout above ₹1,456 may target ₹1,500–₹1,540. Supports at ₹1,410 & ₹1,366. If trend cools, ₹1,380–₹1,400 is a good re-entry zone. Positional SL at ₹1,300. Conclusion: Strong earnings, expansion & bullish charts make Medanta a trend leader in healthcare. Watch ₹1,456 for breakout, and ₹1,380–₹1,400 for entry on dips. Disclosure: No personal/family holding. SEBI Reg. INH000019309. Disclaimer: Informational only; market involves risk. Do your own research.